Barrison Lauren, Park Selena, Decherney Alan
National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 10 Center Drive (Building 10 5 SW-5570), Bethesda, MD 20892, USA.
Shady Grove Fertility, 6400 Brooktree Court, Wexford, PA 15090, USA.
Case Rep Womens Health. 2024 Jul 9;43:e00636. doi: 10.1016/j.crwh.2024.e00636. eCollection 2024 Oct.
This article presents a case of spontaneous conception and live birth in a 40-year-old woman who had undergone gonadotoxic chemotherapy and allogenic stem cell transplant for relapsed acute myelogenous leukemia complicated by treatment-refractory graft-versus-host disease. The patient's follicle stimulating hormone level was 44.4 mIU/mL at age 38 and then decreased to 4.1 mIU/mL at age 41, suggesting ovarian recovery. Her graft-versus-host disease subjectively improved during pregnancy. She ultimately delivered a healthy neonate. This case demonstrates the potential for ovarian recovery after stem allogenic cell transplant in a patient of advanced reproductive age and provides insight into the limited knowledge about graft-versus-host disease in pregnancy. As survival after stem cell transplant continues to improve, understanding the downstream consequences of the treatment, including for fertility and pregnancy, is of growing importance.
本文介绍了一名40岁女性自然受孕并活产的病例。该女性曾因复发的急性髓性白血病接受了性腺毒性化疗和异基因干细胞移植,且并发了治疗难治性移植物抗宿主病。患者38岁时促卵泡激素水平为44.4 mIU/mL,41岁时降至4.1 mIU/mL,提示卵巢恢复。她的移植物抗宿主病在孕期主观上有所改善。她最终产下一名健康的新生儿。该病例证明了高龄生殖期患者异基因干细胞移植后卵巢恢复的可能性,并为孕期移植物抗宿主病方面有限的知识提供了见解。随着干细胞移植后的生存率不断提高,了解该治疗的下游后果,包括对生育和妊娠的影响,变得越来越重要。